A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...
NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results